Ampio Pharmaceuticals (AMPE)
(Delayed Data from OTC)
$0.13 USD
0.00 (0.00%)
Updated Jun 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Ampio Pharmaceuticals, Inc. [AMPE]
Reports for Purchase
Showing records 21 - 39 ( 39 total )
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q21: Phase 3 OAK-KL4 Results Likely Unblinded and Disclosed This Quarter
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q21: Believe Enrolling More Patients Is Best Option for OAK4 Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ampion Reduces COVID-19 Respiratory Distress All-Cause Mortality by 78%
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare -COVID-19 Therapeutics Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
OAK4 Path Forward Awaits FDA Response, COVID-19 Program Progresses
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q20: Began Nebulized Ampion Trial, OAK4 Path Forward Awaits FDA Response
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
EVENT: COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Swift Phase 3 Enrollment Continues - Expecting Top-Line Results in 3Q20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ampio Pharmaceuticals, Inc.
Industry: Medical - Drugs
Enough Clinical Evidence to Warrant Optimism Going into Mid-2020 Phase 3
Provider: Roth Capital Partners, Inc.
Analyst: Research Department